PT  - JOURNAL ARTICLE
AU  - María M. Gonzalez Lopez Ledesma
AU  - Lautaro Sanchez
AU  - Diego S. Ojeda
AU  - Santiago Oviedo Rouco
AU  - Andres H. Rossi
AU  - Augusto Varese
AU  - Ignacio Mazzitelli
AU  - Carla A. Pascuale
AU  - Esteban A. Miglietta
AU  - Pamela E. Rodríguez
AU  - Horacio M. Pallarés
AU  - Guadalupe S. Costa Navarro
AU  - Julio J. Caramelo
AU  - Paul W Rothlauf
AU  - Zhuoming Liu
AU  - Louis-Marie Bloyet
AU  - Marjorie Cornejo Pontelli
AU  - Natali B. Rasetto
AU  - Shirley D. Wenker
AU  - Lila Y. Ramis
AU  - Magalí G. Bialer
AU  - María Jose de Leone
AU  - C. Esteban Hernando
AU  - Luciana Bianchimano
AU  - Antonella Rios
AU  - María Soledad Treffinger Cienfuegos
AU  - Diana R. Rodriguez García
AU  - Yesica Longueira
AU  - Natalia Laufer
AU  - Diego Alvarez
AU  - Ana Ceballos
AU  - Valeria Ochoa
AU  - Cecilia Monzani
AU  - Gariela Turk
AU  - Melina Salvatori
AU  - Jorge Carradori
AU  - Katherine Prost
AU  - Alejandra Rima
AU  - Claudia Varela
AU  - Regina Ercole
AU  - Rosana I. Toro
AU  - Sebastian Gutierrez
AU  - Martín Zubieta
AU  - Dolores Acuña
AU  - Mercedes S. Nabaes Jodar
AU  - Carolina Torres
AU  - Laura Mojsiejczuk
AU  - Mariana Viegas
AU  - Pilar Velazquez
AU  - Clarisa Testa
AU  - Nicolas Kreplak
AU  - Marcelo Yanovsky
AU  - Sean Whelan
AU  - Jorge Geffner
AU  - Marina Pifano
AU  - Andrea V. Gamarnik
TI  - Temporal Increase in Neutralization Potency of SARS-CoV-2 Antibodies and Reduced Viral Variant Escape after Sputnik V Vaccination
AID  - 10.1101/2021.08.22.21262186
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.08.22.21262186
4099  - http://medrxiv.org/content/early/2021/08/25/2021.08.22.21262186.short
4100  - http://medrxiv.org/content/early/2021/08/25/2021.08.22.21262186.full
AB  - Recent studies have shown a temporal increase in the neutralizing antibody potency and breadth to SARS-CoV-2 variants in coronavirus disease 2019 (COVID-19) convalescent individuals. Here, we observed a similar process after Sputnik V vaccination. We examined the longitudinal antibody responses and viral neutralizing capacity to variants of concern (VOCs: Alpha, Beta, Gamma, and Delta) and a broadly spread variant of interest (VOI: Lambda) in volunteers up to 6 months after receiving the Sputnik V vaccine in Argentina. A collection of 1,800 serum samples obtained between January and August 2021 was used. The analysis indicates that while anti-spike IgG levels significantly wane over time, the neutralizing potency to the first-wave linages of SARS-CoV-2 and VOC increases within four months of vaccination, suggesting that antibody maturation occurs. This increase was more evident for the Beta and Gamma variants, which showed the highest propensity for neutralization escape. Our observations suggest that protection increases over the six months following vaccination as a consequence of antibody maturation, resulting in improved potency of antibodies to viral escape mutations.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by NIH (NIAID) R01.AI095175 and PICT-2017-1717, PICT- 2015-2555 to AVG and by the National Ministry of Science Technology and Innovation or Argentina.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the central ethics committee of Buenos Aires province, Argentina. File number: IF-2021-09238265-GDEBA-CECMSALGP. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be available.